Oncolytics Biotech (TSE:ONC) has released an update.
Oncolytics Biotech Inc. reports a promising outlook with feedback from the FDA meeting supporting its breast cancer treatment trials and advances in pancreatic cancer studies, backed by a stable cash position of $24.9 million. The company highlighted progress with pelareorep, its immunotherapeutic agent, including the initiation of dosing in a new pancreatic cancer cohort study and a collaboration for an adaptive pancreatic cancer trial. With these developments, Oncolytics Biotech remains on track to report key trial results in the second half of 2024 and maintains financial stability into 2025.
For further insights into TSE:ONC stock, check out TipRanks’ Stock Analysis page.
